Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 1632061, 9 pages
http://dx.doi.org/10.1155/2016/1632061
Research Article

Fatty Liver and Insulin Resistance in the Liver-Specific Knockout Mice of Mitogen Inducible Gene-6

1Research Center for Drug Discovery Technology, Division of Drug Discovery Research, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea
2Department of Drug Development and Discovery, Graduate School of New Drug Development and Discovery, Chungnam National University, Daejeon, Republic of Korea
3Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Republic of Korea

Received 11 April 2016; Revised 21 October 2016; Accepted 24 October 2016

Academic Editor: Hiroshi Okamoto

Copyright © 2016 Byung Kil Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K.-L. Lee, K. R. Isham, L. Stringfellow, R. Rothrock, and F. T. Kenney, “Molecular cloning of cDNAs cognate to genes sensitive to hormonal control in rat liver,” Journal of Biological Chemistry, vol. 260, no. 30, pp. 16433–16438, 1985. View at Google Scholar · View at Scopus
  2. M. Fiorini, C. Ballarò, G. Sala, G. Falcone, S. Alemà, and O. Segatto, “Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control,” Oncogene, vol. 21, no. 42, pp. 6530–6539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Xu, A. Makkinje, and J. M. Kyriakis, “Gene 33 is an endogenous inhibitor of Epidermal Growth Factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function,” Journal of Biological Chemistry, vol. 280, no. 4, pp. 2924–2933, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. Xu, R. D. Patten, T. Force, and J. M. Kyriakis, “Gene 33/RALT is induced by hypoxia in cardiomyocytes, where it promotes cell death by suppressing phosphatidylinositol 3-kinase and extracellular signal-regulated kinase survival signaling,” Molecular and Cellular Biology, vol. 26, no. 13, pp. 5043–5054, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-W. Zhang, B. Staal, Y. Su et al., “Evidence that MIG-6 is a tumor-suppressor gene,” Oncogene, vol. 26, no. 2, pp. 269–276, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Makkinje, D. A. Quinn, A. Chen et al., “Gene 33/mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress,” Journal of Biological Chemistry, vol. 275, no. 23, pp. 17838–17847, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Fiorentino, C. Pertica, M. Fiorini et al., “Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain,” Molecular and Cellular Biology, vol. 20, no. 20, pp. 7735–7750, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Amatschek, U. Koenig, H. Auer et al., “Tissue-wide expression profiling using cdna subtraction and microarrays to identify tumor-specific genes,” Cancer Research, vol. 64, no. 3, pp. 844–856, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 103, no. 2, pp. 211–225, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. W. P. Carney, K. Leitzel, S. Ali, R. Neumann, and A. Lipton, “HER-2 therapy. HER-2/neu diagnostics in breast cancer,” Breast Cancer Research, vol. 9, article 207, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Hu, W. Liu, J. Mendelsohn et al., “Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells,” Journal of the National Cancer Institute, vol. 89, no. 17, pp. 1271–1276, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Selvaggi, S. Novello, V. Torri et al., “Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer,” Annals of Oncology, vol. 15, no. 1, pp. 28–32, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Ciardiello, R. Caputo, R. Bianco et al., “Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor,” Clinical Cancer Research, vol. 6, no. 5, pp. 2053–2063, 2000. View at Google Scholar · View at Scopus
  14. M. Breccia, M. Muscaritoli, Z. Aversa, F. Mandelli, and G. Alimena, “Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment,” Journal of Clinical Oncology, vol. 22, no. 22, pp. 4653–4655, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. P. O. Prada, E. R. Ropelle, R. H. Mourão et al., “EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice,” Diabetes, vol. 58, no. 12, pp. 2910–2919, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. B. J. Ku, T. H. Kim, J. H. Lee et al., “Mig-6 plays a critical role in the regulation of cholesterol homeostasis and bile acid synthesis,” PLOS ONE, vol. 7, no. 8, Article ID e42915, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. J.-Y. Yoo, T. H. Kim, S. Kong et al., “Role of Mig-6 in hepatic glucose metabolism,” Journal of Diabetes, vol. 8, no. 1, pp. 86–97, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Yabaluri and M. D. Bashyam, “Hormonal regulation of gluconeogenic gene transcription in the liver,” Journal of Biosciences, vol. 35, no. 3, pp. 473–484, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Jitrapakdee, “Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis,” International Journal of Biochemistry and Cell Biology, vol. 44, no. 1, pp. 33–45, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Krssak, A. Brehm, E. Bernroider et al., “Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes,” Diabetes, vol. 53, no. 12, pp. 3048–3056, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Gastaldelli, Y. Miyazaki, M. Pettiti et al., “Metabolic effects of visceral fat accumulation in type 2 diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 5098–5103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Shimano, J. D. Horton, R. E. Hammer, I. Shimomura, M. S. Brown, and J. L. Goldstein, “Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a,” Journal of Clinical Investigation, vol. 98, no. 7, pp. 1575–1584, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Shimomura, R. E. Hammer, J. A. Richardson et al., “Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy,” Genes and Development, vol. 12, no. 20, pp. 3182–3194, 1998. View at Publisher · View at Google Scholar · View at Scopus
  24. Q. M. Anstee and R. D. Goldin, “Mouse models in non-alcoholic fatty liver disease and steatohepatitis research,” International Journal of Experimental Pathology, vol. 87, no. 1, pp. 1–16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. E. Moller, “Potential role of TNF-α in the pathogenesis of insulin resistance and type 2 diabetes,” Trends in Endocrinology and Metabolism, vol. 11, no. 6, pp. 212–217, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. G. S. Hotamisligil and B. M. Spiegelman, “Tumor necrosis factor α: a key component of the obesity-diabetes link,” Diabetes, vol. 43, no. 11, pp. 1271–1278, 1994. View at Google Scholar · View at Scopus
  27. J. C. Lee, B. K. Park, S. Choung et al., “Amelioration of hypercholesterolemia by an EGFR tyrosine kinase inhibitor in mice with liver-specific knockout of Mig-6,” PLoS ONE, vol. 9, no. 12, Article ID e114782, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. A. B. Keeton, J. Xu, J. L. Franklin, and J. L. Messina, “Regulation of Gene33 expression by insulin requires MEK-ERK activation,” Biochimica et Biophysica Acta, vol. 1679, no. 3, pp. 248–255, 2004. View at Publisher · View at Google Scholar · View at Scopus